Swipe om te navigeren naar een ander artikel
The authors Andrea Picchianti Diamanti and Valentina Germano contributed equally to this work.
To assess health-related quality of life (HR-QoL) in patients with Rheumatoid arthritis (RA), early RA and early psoriatic arthritis (PsA), and to evaluate the efficacy of etanercept in reducing disability.
Twenty healthy volunteers, 40 RA, 20 early RA and 20 early PsA patients were recruited. All patients received etanercept plus methotrexate. Assessments at baseline and after 2 years’ therapy included Disease Activity Scores on 44 joints [DAS44], Health Assessment Questionnaire (HAQ) scores and Short Form-36 (SF-36) scores.
HAQ and SF-36 scores were significantly worse in patients with RA, early RA or early PsA than in healthy volunteers. The HAQ score at baseline was significantly higher in RA patients than in patients with early RA or early PsA, whereas the scores were similar in patients with early RA and early PsA. Patients with early RA had greater impairment than patients with early PsA in several areas of disability. After 2 years’ treatment, HAQ scores and SF-36 summary and subscale scores improved significantly in the three patient groups.
This study suggests that early PsA is a less disabling disease than RA or early RA. It confirms the efficacy of etanercept in reducing disease severity and improving HR-QoL and suggests that early therapeutic intervention may lead to greater improvement in the mental and emotional components of these diseases.
Log in om toegang te krijgen
Met onderstaand(e) abonnement(en) heeft u direct toegang:
Woolacott, N. F., Khadjesari, Z. C., Bruce, I. N., et al. (2006). Etanercept and infliximab for the treatment of psoriatic arthritis: A systematic review. Clinical and Experimental Rheumatology, 24, 587–593. PubMed
Kane, D., Stafford, L., Bresnihan, B., et al. (2003). A prospective, clinical and radiological study of early psoriatic arthritis: An early synovitis clinic experience. Rheumatology (Oxford), 42, 1460–1468. CrossRef
Smolen, J. S., Aletaha, D., Machold, K. P., et al. (2005). Therapeutic strategies in early rheumatoid arthritis. Bailliere’s Best Practice and research Clinical Rheumatology, 19, 163–177. CrossRef
Donahue, K. E., Gartlehner, G., Jonas, D. E., et al. (2008). Systematic review: Comparative effectiveness and harms of disease-modifying medications for rheumatoid arthritis. Annals of Internal Medicine, 148, 124–134. PubMed
World Health Organization. World Health Organization: classification of impairments, disabilities and handicaps. Geneva: WHO, 1980.
Bruce, B., & Fries, J. F. (2005). The health assessment questionnaire (HAQ). Clinical and Experimental Rheumatology, 23, S14–S18. PubMed
Sokoll, K. B., & Helliwell, P. S. (2001). Comparison of disability and quality of life in rheumatoid and psoriatic arthritis. Journal of Rheumatology, 28, 1842–1846. PubMed
Husted, J. A., Gladman, D. D., Farewell, V. T., Long, J. A., & Cook, R. J. (2007). Validating the SF-36 health questionnaire in patients with psoriatic arthritis. Journal of Rheumatology, 24, 511–517.
Van der Heijde, D., Klareskog, L., Rodriguez-Valverde, V., et al. (2006). Comparison of etanercept and methotrexate, alone and combined, in the treatment of rheumatoid arthritis: Two-year clinical and radiographic results from the TEMPO study, a double-blind, randomized trial. Arthritis and Rheumatism, 54, 1063–1074. CrossRefPubMed
Moreland, L. W., Weinblatt, M. E., Keystone, E. C., et al. (2006). Etanercept treatment in adults with established rheumatoid arthritis: 7 years of clinical experience. Journal of Rheumatology, 33, 854–861. PubMed
Genovese, M. C., Bathon, J. M., Fleischmann, R. M., et al. (2005). Longterm safety, efficacy, and radiographic outcome with etanercept treatment in patients with early rheumatoid arthritis. Journal of Rheumatology, 32, 1232–1242. PubMed
- Health-related quality of life and disability in patients with rheumatoid, early rheumatoid and early psoriatic arthritis treated with etanercept
- Springer Netherlands